Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
Status:
Completed
Trial end date:
2017-10-18
Target enrollment:
Participant gender:
Summary
The general aim of the trial is to assess the efficacy of one year treatment with long-acting
somatostatin analogue (Octreotide LAR) compared with placebo in slowing kidney and liver
growth rate in patients with ADPKD and moderate/severe renal insufficiency and to assess
whether and to which extent this translates into slower renal function decline over 3-year
follow-up.
Phase:
Phase 3
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research